Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models

Neoplasia

Volumn 6, Issue 4, 2004, Pages 343-353

  Peer, Dan ^a   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Doxorubicin; Drug delivery; Hyaluronan; Nanoliposomes; Targeting

Indexed keywords

DOXORUBICIN; DRUG CARRIER; HYALURONAN NANOLIPOSOME; HYALURONIC ACID; LIPOSOME; MACROGOL; MITOMYCIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RESPONSE; DRUG TARGETING; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; ISOGRAFT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG CARRIERS; HUMANS; HYALURONIC ACID; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 3142783426     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.03460     Document Type: Article

References (42)

1. Allen TM (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2, 750-763.
2. Gabizon AA (2002). Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 10, 535-538.
3. Gabizon A, Shmeeda H, and Barenholz Y (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42, 419-436.
4. Sapra P and Allen TM (2003). Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42, 439-462.
5. Kim JA (2003). Targeted therapies for the treatment of cancer. Am J Surg 186, 264-268.
6. Goldman JM and Melo JV (2003). Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349, 1451-1464.
7. Margalit R (1995). Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carr Syst 12, 233-261.
8. Margalit R (1998). Bioadhesive liposomes in topical treatment of wounds. In Berenstein, CH (Ed.), Microparticulates-Preparation, Characterization and Application in Medicine, pp. 425-461 Marcel Dekker, Inc., New York.
9. Gabizon AA (2001). Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19, 424-436.
10. Moghimi SM, Hunter AC, and Murray JC (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53, 283-318.
11. Forssen EA, Coulter DM, and Proffit RC (1992). Selective localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52, 3255-3261.
12. Allen TM (1994). Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15, 215-220.
13. Oku N and Namba Y (1994). Long-circulating liposomes. Crit Rev Ther Drug Carr Syst 11, 231-270.
14. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, and Madden TD (2000). Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60, 3389-3393.
15. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, and Redemann C (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88, 11460-11464.
16. Peer D and Margalit R (2004). Loading mitomycin C inside long-circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108, 780-789.
17. Waterhouse DN, Tardi PG, Mayer LD, and Bally MB (2001). A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24, 903-920.
18. Tseng YL, Hong RL, Tao MH, and Chang FH (1999). Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma mode. Int J Cancer 80, 723-730.
19. Koning GA, Morselt HW, Gorter A, Allen TM, Zalipsky S, Kamps JA, and Scherphof GL (2001). Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharm Res 18, 1291-1298.
20. Yerushalmi N and Margalit R (1994). Bioadhesive, collagen-modified liposomes: molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers. Biochim Biophys Acta 1189, 13-20.
21. Yerushalmi N, Arad A, and Margalit R (1994). Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 313, 267-273.
22. Yerushalmi N and Margalit R (1998). Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys 349, 21-26.
23. Peer D and Margalit R (2000). Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch Biochem Biophys 383, 185-190.
24. Peer D, Florentin A, and Margalit R (2003). Hyaluronan is a key component of cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta 1612, 76-82.
25. Zöller M (1995). CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 73, 425-438.
26. Smadja-Joff F, Legras S, Girard N, Li Y, Delpech B, Bloget F, Morimoto K, Le Bousse-Kerdile C, Clay D, Jasmin C, and Levesque JP (1996). CD44 and hyaluronan binding by human myeloid cells. Leuk Lymphoma 21, 407-420.
27. Rudzki Z and Jothy S (1997). CD44 and the adhesion of neoplastic cells. Mol Pathol 50, 57-71.
28. Sneath RJ and Mangham DC (1998). The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51, 191-200.
29. Tran TA, Kallakury BV, Sheehan CE, and Ross JS (1997). Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28, 809-814.
30. Gallatin M, St Joh TP, Siegelman M, Reichert R, Butcher EC, and Weissman IL (1986). Lymphocyte homing receptors. Cell 44, 673-680.
31. Li H, Guo L, Li JW, Liu N, Qi R, and Liu J (2000). Expression of Hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 17, 927-932.
32. Abetamann V, Kern HF, and Elsasser HP (1996). Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 2, 1607-1618.
33. Bartolazzi A, Peach R, Aruffo A, and Stamenkovic I (1994). Interaction between CD44, and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 180, 53-66.
34. Chiu RK, Carpenito C, Dougherty ST, Hayes GM, and Dougherty GJ (1999). Identification and characterization of CD44RC, a novel alternatively spliced soluble CD44 isoform that can potentiate the hyaluronan binding activity of cell surface CD44. Neoplasia 1, 446-452.
35. Birch M, Mitchell S, and Hart IR (1991). Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51, 6660-6667.
36. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, and Winer E (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94, 25-36.
37. Mitra S, Gaur U, Ghosh PC, and Maitra AN (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 74, 317-323.
38. Yoo HS, Lee KH, Oh JE, and Park TG (2000). In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 68, 419-431.
39. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, and Mayer LD (2000). Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60, 2964-2972.
40. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, and Kloog Y (2002). The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8, 555-565.
41. Gabizon A, Tzemach D, Mak L, Bronstein M, and Horowitz AT (2002). Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10, 539-548.
42. Droll A, Dougherty ST, Chiu RK, Dirks JF, McBride WH, Cooper DL, and Dougherty GJ (1995). Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem 270, 11567-11573.